Overview

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ranibizumab